[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Merus N.V. Common Shares (MRUS)

Merus N.V. Common Shares (MRUS) price hits a 52-week and all-time high of $XXXXX following acquisition news from Genmab and positive clinical trial results for petosemtamab.

### About Merus N.V. Common Shares
Merus N.V. is a biotechnology company focused on developing antibody-based therapeutics for cancer.  
Merus N.V. Common Shares uses the ticker $MRUS for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Merus N.V. Common Shares (MRUS) trading volume is up XXXXX% from the previous week.
- Merus N.V. Common Shares (MRUS) sentiment is up XXXXXX% from the previous week.
- Merus N.V. Common Shares (MRUS) creators is up XXXXX% from the previous week.
- Merus N.V. Common Shares Price hit a 52-Week high of $XXXXX for the hour
- Merus N.V. Common Shares Price hit an all time of $XXXXX for the hour

### Price: $XXXXX
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/close.tsv)  
The stock price has surged to a 52-week high, driven by the acquisition news from Genmab at a significant premium and positive clinical trial results for its lead drug candidate, petosemtamab. Recent social media activity shows increased mentions in 13F filings and collaboration news, reflecting strong market confidence.  

24-Hour: XXXX%
7-Day: XXXX%
30-Day: XXXX%

1-Year High: $XX on 2025-12-10  
1-Year Low: $XXXXX on 2025-04-08  
  
  
### AltRank: XXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/alt_rank.tsv)  
Merus N.V. Common Shares (MRUS) is currently AltRank #964 based on combined combined social and market metrics
Daily Average: XXX  
X Week: XXXXX +571  
X Month: XXXXX +258  
X Months: XXXXX +1,283  
X Year: XXXXX +1,352  
1-Year High: XXXXX on 2025-08-12  
1-Year Low: XX on 2025-05-25  
  
  
### Galaxy Score: XXXXX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/galaxy_score.tsv)  
Current Value: XXXXX  
Daily Average: XX  
X Week: XX +2  
X Month: XX +3  
X Months: XX -XX  
X Year: XX -X  
1-Year High: XX on 2025-07-10  
1-Year Low: XX on 2025-09-19  
  
  
### Engagements: XXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/interactions.tsv)  
Current Value: XXX  
Daily Average: XXXXXX  
X Week: XXXXX -XX%  
X Month: XXXXXXX -XXXX%  
X Months: XXXXXXXXX +69%  
X Year: XXXXXXXXX -XX%  
1-Year High: XXXXXXX on 2025-09-29  
1-Year Low: XX on 2025-12-06  

Engagements by network (24h):
X: XXX

  
  
### Mentions: XX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/posts_active.tsv)  
Current Value: XX  
Daily Average: XXX  
X Week: XXX -XXXX%  
X Month: XXX -XX%  
X Months: XXXXX +102%  
X Year: XXXXX +423%  
1-Year High: XXXXX on 2025-07-10  
1-Year Low: X on 2025-12-07  

Mentions by network (24h):
X: XX

  
  
### Creators: XX (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning Merus N.V. Common Shares (MRUS) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX  
X Week: XXX +15%  
X Month: XXX -XX%  
X Months: XXXXX +81%  
X Year: XXXXX +585%  
1-Year High: XXX on 2025-09-29  
1-Year Low: X on 2025-12-07  

The most influential creators that mention Merus N.V. Common Shares in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@NightOwlBiotech](/creator/twitter/NightOwlBiotech) | X    | XXXXX     | X     | XX          |
| [@AnotherBio](/creator/twitter/AnotherBio)           | X    | XXXXX     | X     | XX          |
| [@Biobeats99](/creator/twitter/Biobeats99)           | X    | XXX       | X     | XX          |
| [@JoseRestonVA](/creator/twitter/JoseRestonVA)       | X    | XXXXX     | X     | XX          |

[View More](/list/creators/$mrus/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Week: XXX% +67%  
X Month: XXX% +33%  
X Months: XXX% +11%  
X Year: XXX% +42%  
1-Year High: XXX% on 2025-01-26  
1-Year Low: XX% on 2024-12-29  

Most Supportive Themes:
- Acquisition by Genmab: (30%) Genmab's agreement to acquire Merus for $X billion, with multiple rounds of bidding and a significant premium, indicates strong investor confidence in Merus's pipeline and potential.
- Promising Drug Trial Data: (25%) Positive results for petosemtamab in head and neck cancer, showing a high response and survival rate, presented at ASCO 2025, have driven analyst upgrades and stock surges.
- Analyst Upgrades and Price Targets: (20%) Analysts have raised their price targets for Merus, citing the promising clinical trial data and the potential of its drug candidates, further boosting investor sentiment.
  
Most Critical Themes:
- Risk Factor Disclosures: (15%) Merus has flagged rising net losses, expanded clinical and commercialization risks, and heavy reliance on partners, alongside new uncertainties from pending transactions.
- Regulatory and Market Acceptance Challenges: (10%) The company faces heightened challenges in intellectual property, regulatory approvals, supply chain, and market acceptance, as well as warnings on side effects and patient enrollment.
  
  
  
### Social Dominance: XXXXXXX%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/social_dominance.tsv)  
Current Value: XXXXXXX%  
Daily Average: XXXXX%  
X Week: XXXXXX% -XXXXXX%  
X Month: XXXXXX% +0.002%  
X Months: XXXXXX% -XXXXX%  
X Year: XXXXXX% -XXXXX%  
1-Year High: XXXXX% on 2025-07-10  
1-Year Low: XXXXXX% on 2025-12-07  
  
  
### Market Dominance: XXXXXXX%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/market_dominance.tsv)  
Current Value: XXXXXXX%  
Daily Average: X%  
1-Year High: XXXXX% on 2025-11-23  
1-Year Low: XXXXXXX% on 2025-03-19  
  
  
### Market Cap: $XXXXXXXXXXXXX
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$mrus/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$mrus/time-series/market_cap.tsv)  
Current Value: $XXXXXXXXXXXXX  
Daily Average: $XXXXXXXXXXXXX  
X Week: $XXXXXXXXXXXXX +$0.95%  
X Month: $XXXXXXXXXXXXX +$1.80%  
X Months: $XXXXXXXXXXXXX +$78%  
X Year: $XXXXXXXXXXXXX +$145%  
1-Year High: $XXXXXXXXXXXXX on 2025-12-09  
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08  

### Top Merus N.V. Common Shares Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"🔴🔥 $MRUS Merus N.V. Approves Acquisition by Genmab A/S and Appoints New Directors On December X 2025 Merus N. #SEC #8K #Pharma #Biotech"  
[X Link](https://x.com/booooogy01/status/1998498630995755171) [@booooogy01](/creator/x/booooogy01) 2025-12-09T21:02Z X followers, XX engagements


"Wowwww $LYEL $FATE $ALLO $CRBU $ADPT $PSNL $BNR $NTRA $TWST $GH $EXAS $NVTA $PSNL $BNR $NTRA $TWST $GH $EXAS $NVTA $ZNTL $EOLS $PTCT $VKTX $MCRB $JANX $NKTX $CARM $FHTX $KURA $VOR $MRUS $RCKT $ARQT $SANA $DYN $FULC"  
[X Link](https://x.com/BuyTheUgly/status/1998484590315581451) [@BuyTheUgly](/creator/x/BuyTheUgly) 2025-12-09T20:07Z XX followers, XXX engagements


"$NUVB analyst consensus revenue estimates v. the same for $MRUS the day acquired by $GMAB for an EV of $7.3B & MRUS mgmt's forecast Analysts project NUVB to generate XX% MRUS sales @ peak yet its MC = 40%. This is not investment advice. NUVB estimates c/b fiction $IBB $XBI"  
[X Link](https://x.com/NightOwlBiotech/status/1997708952331849870) [@NightOwlBiotech](/creator/x/NightOwlBiotech) 2025-12-07T16:45Z 1663 followers, 1037 engagements


"$MRUS Guys Don't miss the Target price for Next Week. 💸🔜"  
[X Link](https://x.com/HollPabla39969/status/1997668281960870056) [@HollPabla39969](/creator/x/HollPabla39969) 2025-12-07T14:03Z XX followers, XX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Merus N.V. Common Shares (MRUS)

Merus N.V. Common Shares (MRUS) price hits a 52-week and all-time high of $XXXXX following acquisition news from Genmab and positive clinical trial results for petosemtamab.

About Merus N.V. Common Shares

Merus N.V. is a biotechnology company focused on developing antibody-based therapeutics for cancer.
Merus N.V. Common Shares uses the ticker $MRUS for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Merus N.V. Common Shares (MRUS) trading volume is up XXXXX% from the previous week.
Merus N.V. Common Shares (MRUS) sentiment is up XXXXXX% from the previous week.
Merus N.V. Common Shares (MRUS) creators is up XXXXX% from the previous week.
Merus N.V. Common Shares Price hit a 52-Week high of $XXXXX for the hour
Merus N.V. Common Shares Price hit an all time of $XXXXX for the hour

Price: $XXXXX

Price 24-Hour Time-Series Raw Data
The stock price has surged to a 52-week high, driven by the acquisition news from Genmab at a significant premium and positive clinical trial results for its lead drug candidate, petosemtamab. Recent social media activity shows increased mentions in 13F filings and collaboration news, reflecting strong market confidence.

24-Hour: XXXX% 7-Day: XXXX% 30-Day: XXXX%

1-Year High: $XX on 2025-12-10
1-Year Low: $XXXXX on 2025-04-08

AltRank: XXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Merus N.V. Common Shares (MRUS) is currently AltRank #964 based on combined combined social and market metrics Daily Average: XXX
X Week: XXXXX +571
X Month: XXXXX +258
X Months: XXXXX +1,283
X Year: XXXXX +1,352
1-Year High: XXXXX on 2025-08-12
1-Year Low: XX on 2025-05-25

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +2
X Month: XX +3
X Months: XX -XX
X Year: XX -X
1-Year High: XX on 2025-07-10
1-Year Low: XX on 2025-09-19

Engagements: XXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXXX
X Week: XXXXX -XX%
X Month: XXXXXXX -XXXX%
X Months: XXXXXXXXX +69%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-09-29
1-Year Low: XX on 2025-12-06

Engagements by network (24h): X: XXX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XXXX%
X Month: XXX -XX%
X Months: XXXXX +102%
X Year: XXXXX +423%
1-Year High: XXXXX on 2025-07-10
1-Year Low: X on 2025-12-07

Mentions by network (24h): X: XX

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Merus N.V. Common Shares (MRUS) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX
X Week: XXX +15%
X Month: XXX -XX%
X Months: XXXXX +81%
X Year: XXXXX +585%
1-Year High: XXX on 2025-09-29
1-Year Low: X on 2025-12-07

The most influential creators that mention Merus N.V. Common Shares in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@NightOwlBiotech	X	XXXXX	X	XX
@AnotherBio	X	XXXXX	X	XX
@Biobeats99	X	XXX	X	XX
@JoseRestonVA	X	XXXXX	X	XX

Sentiment: XXX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Week: XXX% +67%
X Month: XXX% +33%
X Months: XXX% +11%
X Year: XXX% +42%
1-Year High: XXX% on 2025-01-26
1-Year Low: XX% on 2024-12-29

Most Supportive Themes:

Acquisition by Genmab: (30%) Genmab's agreement to acquire Merus for $X billion, with multiple rounds of bidding and a significant premium, indicates strong investor confidence in Merus's pipeline and potential.
Promising Drug Trial Data: (25%) Positive results for petosemtamab in head and neck cancer, showing a high response and survival rate, presented at ASCO 2025, have driven analyst upgrades and stock surges.
Analyst Upgrades and Price Targets: (20%) Analysts have raised their price targets for Merus, citing the promising clinical trial data and the potential of its drug candidates, further boosting investor sentiment.

Most Critical Themes:

Risk Factor Disclosures: (15%) Merus has flagged rising net losses, expanded clinical and commercialization risks, and heavy reliance on partners, alongside new uncertainties from pending transactions.
Regulatory and Market Acceptance Challenges: (10%) The company faces heightened challenges in intellectual property, regulatory approvals, supply chain, and market acceptance, as well as warnings on side effects and patient enrollment.

Social Dominance: XXXXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXXX% -XXXXXX%
X Month: XXXXXX% +0.002%
X Months: XXXXXX% -XXXXX%
X Year: XXXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-07-10
1-Year Low: XXXXXX% on 2025-12-07

Market Dominance: XXXXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-11-23
1-Year Low: XXXXXXX% on 2025-03-19

Market Cap: $XXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX +$0.95%
X Month: $XXXXXXXXXXXXX +$1.80%
X Months: $XXXXXXXXXXXXX +$78%
X Year: $XXXXXXXXXXXXX +$145%
1-Year High: $XXXXXXXXXXXXX on 2025-12-09
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08

Top Merus N.V. Common Shares Social Posts

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"🔴🔥 $MRUS Merus N.V. Approves Acquisition by Genmab A/S and Appoints New Directors On December X 2025 Merus N. #SEC #8K #Pharma #Biotech"
X Link @booooogy01 2025-12-09T21:02Z X followers, XX engagements

"Wowwww $LYEL $FATE $ALLO $CRBU $ADPT $PSNL $BNR $NTRA $TWST $GH $EXAS $NVTA $PSNL $BNR $NTRA $TWST $GH $EXAS $NVTA $ZNTL $EOLS $PTCT $VKTX $MCRB $JANX $NKTX $CARM $FHTX $KURA $VOR $MRUS $RCKT $ARQT $SANA $DYN $FULC"
X Link @BuyTheUgly 2025-12-09T20:07Z XX followers, XXX engagements

"$NUVB analyst consensus revenue estimates v. the same for $MRUS the day acquired by $GMAB for an EV of $7.3B & MRUS mgmt's forecast Analysts project NUVB to generate XX% MRUS sales @ peak yet its MC = 40%. This is not investment advice. NUVB estimates c/b fiction $IBB $XBI"
X Link @NightOwlBiotech 2025-12-07T16:45Z 1663 followers, 1037 engagements

"$MRUS Guys Don't miss the Target price for Next Week. 💸🔜"
X Link @HollPabla39969 2025-12-07T14:03Z XX followers, XX engagements